(Q34253331)

English

11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

type-1 diabetes

0 references

0 references

type 2 diabetes

0 references

metabolic syndrome

1 reference

based on heuristic

inferred from title

pathophysiology

1 reference

based on heuristic

inferred from title

Cidália D. Pereira

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Rosário Monteiro

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Maria João Martins

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

I Azevedo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

8 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

869-881

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Regulation of the hypothalamic-pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome--11beta-hydroxysteroid dehydrogenase type 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Does central obesity reflect "Cushing's disease of the omentum"?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Direct protein-protein interaction of 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic reticulum lumen.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-Hydroxysteroid dehydrogenase 1 reductase activity is dependent on a high ratio of NADPH/NADP(+) and is stimulated by extracellular glucose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Hypothalamic-pituitary-adrenal (HPA) axis functioning in relation to body fat distribution

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

The metabolic syndrome: time to get off the merry-go-round?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Nutritional strategies in the prevention and treatment of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

The metabolic syndrome: concepts and controversy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Obesity affects the liver - the link between adipocytes and hepatocytes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Current therapeutic strategies in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Association between the metabolic syndrome and serum cortisol in overweight Latino youth

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

A transgenic model of visceral obesity and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Diet and the role of 11beta-hydroxysteroid dehydrogenase-1 on obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Modulation of glucocorticoid action and the treatment of type-2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Obesity is accompanied by disturbances in peripheral glucocorticoid metabolism and changes in FA recycling.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Weight loss after gastric bypass surgery in women is followed by a metabolically favorable decrease in 11beta-hydroxysteroid dehydrogenase 1 expression in subcutaneous adipose tissue.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Natural products in drug discovery

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Plant polyphenols: chemical properties, biological activities, and synthesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Flavonoids health benefits and their molecular mechanism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

The influence of beverage composition on delivery of phenolic compounds from coffee and tea.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Coffee and type 2 diabetes: from beans to beta-cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Coffee consumption and risk of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Coffee consumption and risk of type 2 diabetes: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Coffee inhibits the reactivation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: a glucocorticoid connection in the anti-diabetic action of coffee?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Different responsiveness in body weight and hepatic 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1 mrna to 11beta-HSD inhibition by glycyrrhetinic acid treatment in obese and lean zucker rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Selective inhibition of 11beta-hydroxysteroid dehydrogenase 1 by 18alpha-glycyrrhetinic acid but not 18beta-glycyrrhetinic acid

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Differential effects of fat and sucrose on body composition in A/J and C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Dietary fatty acid composition alters 11β-hydroxysteroid dehydrogenase type 1 gene expression in rat retroperitoneal white adipose tissue

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

High fructose diets increase 11β-hydroxysteroid dehydrogenase type 1 in liver and visceral adipose in rats within 24-h exposure.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Fructose consumption as a risk factor for non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Metabolic effects of fructose and the worldwide increase in obesity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Fructose and metabolic diseases: new findings, new questions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Calcium intake is inversely associated with metabolic syndrome in postmenopausal women: Korea National Health and Nutrition Survey, 2001 and 2005.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Clinical efficacy of magnesium supplementation in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Upregulation of hepatic 11β-hydroxysteroid dehydrogenase-1 expression in calcium-deficient rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Small for gestational age and magnesium in cord blood platelets: intrauterine magnesium deficiency may induce metabolic syndrome in later life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Magnesium deficiency in pregnant rats alters methylation of specific cytosines in the hepatic hydroxysteroid dehydrogenase-2 promoter of the offspring.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Perhydroquinolylbenzamides as novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Synthesis of potent and orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor HSD-016.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Dehydroepiandrosterone metabolites and their interactions in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Endogenous selective inhibitors of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Effects of bile acids on rat hepatic microsomal type I 11beta-hydroxysteroid dehydrogenase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Effect of chenodeoxycholic acid on 11beta-hydroxysteroid dehydrogenase in various target tissues

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11β-hydroxysteroid dehydrogenase type 1 inhibitor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Differential inhibition of 11 beta-hydroxysteroid dehydrogenase by carbenoxolone in rat brain regions and peripheral tissues

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11beta-hydroxysteroid dehydrogenase 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Apparent mineralocorticoid excess syndrome: an overview

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01582.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2012.01582.X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22321826%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34253331&oldid=1242934916"